FOLH1 and prostate cancer: A prospective translational study by Andrews et al. examined plasma levels of prostate-specific membrane antigen-positive extracellular vesicles (PSMA+ EVs) in patients with hormone-sensitive oligorecurrent prostate cancer enrolled in the ORIOLE and STOMP-like cohorts [18].